Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV Specific Cytokine Secreting TCR-T Cells in EBV-Positive Nasopharyngeal Carcinoma
NCT04509726Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2023
- Primary completion
- Jan 2026
- Countries
- 1
- Sponsor
- Xinqiao Hospital
- Modality
- TCR-Engineered T Cells
- Conditions
- nasopharyngeal carcinoma (NPC)
01
Overview
Phase 2, open-label, single-arm trial of EBV-specific TCR-T cell with cytokine auto-secreting element in nasopharyngeal carcinoma (NPC), sponsored by Xinqiao Hospital. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Mar 2023; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
EBV TCR-T
Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element
03
Who it enrols
Patients with EBV-positive metastatic or recurrent nasopharyngeal carcinoma, ECOG PS 0-2, adequate organ function, and no active infections or other malignancies.
04
Endpoints
Primary
Maximum Tolerated Dose
Beyond the preview
Go deeper on NCT04509726.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509726.